# Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Source: https://onco.cc/trials/nct06767514/  
OnCo record `nct06767514` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Ivonescimab, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Summit Therapeutics, now recruiting.

## Summary

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 is a phase 3 interventional study registered as NCT06767514 by Summit Therapeutics, with 780 participants planned, started 2025-02-27 and due to reach its primary completion in 2028-04. Interventions recorded: Ivonescimab Injection, Pembrolizumab Injection. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06767514
- Phase: 3
- Setting: A Randomized, Double-blinded, Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression
- Sponsor: Summit Therapeutics
- Enrolled: 780

## Sources

- ClinicalTrials.gov NCT06767514: https://clinicaltrials.gov/study/NCT06767514

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Ivonescimab](https://onco.cc/drugs/ivonescimab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Summit Therapeutics](https://onco.cc/companies/summit-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06767514.json